End-of-day quote
Shenzhen S.E.
18:00:00 2024-05-16 EDT
|
5-day change
|
1st Jan Change
|
5.38
CNY
|
+0.37%
|
|
-4.95%
|
-13.78%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
3,261
|
3,341
|
9,770
|
8,095
|
4,779
|
5,097
|
Enterprise Value (EV)
1 |
3,488
|
3,920
|
10,340
|
8,609
|
5,453
|
5,801
|
P/E ratio
|
46.9
x
|
1,319
x
|
1,300
x
|
-25.1
x
|
-61
x
|
-205
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
5.24
x
|
5.32
x
|
13.2
x
|
11.3
x
|
6
x
|
4.88
x
|
EV / Revenue
|
5.61
x
|
6.24
x
|
14
x
|
12
x
|
6.85
x
|
5.55
x
|
EV / EBITDA
|
30.2
x
|
35.6
x
|
89.8
x
|
-1,557
x
|
912
x
|
34.3
x
|
EV / FCF
|
10.1
x
|
-49.2
x
|
26
x
|
41.6
x
|
-3.58
x
|
-107
x
|
FCF Yield
|
9.86%
|
-2.03%
|
3.85%
|
2.4%
|
-27.9%
|
-0.94%
|
Price to Book
|
2.78
x
|
3.24
x
|
7.52
x
|
8.31
x
|
3.43
x
|
3.73
x
|
Nbr of stocks (in thousands)
|
819,430
|
816,900
|
816,900
|
816,900
|
816,900
|
816,900
|
Reference price
2 |
3.980
|
4.090
|
11.96
|
9.910
|
5.850
|
6.240
|
Announcement Date
|
19-04-22
|
20-04-23
|
21-04-26
|
22-04-27
|
23-04-25
|
24-04-25
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
622.1
|
628.3
|
738.7
|
714.7
|
795.9
|
1,045
|
EBITDA
1 |
115.6
|
110.1
|
115.1
|
-5.53
|
5.982
|
169.2
|
EBIT
1 |
48.68
|
37.41
|
26.21
|
-112
|
-99.16
|
69.43
|
Operating Margin
|
7.83%
|
5.95%
|
3.55%
|
-15.67%
|
-12.46%
|
6.64%
|
Earnings before Tax (EBT)
1 |
107
|
9.634
|
0.585
|
-504.2
|
-133.8
|
33.73
|
Net income
1 |
69.44
|
2.543
|
7.504
|
-322.2
|
-78.33
|
-24.93
|
Net margin
|
11.16%
|
0.4%
|
1.02%
|
-45.08%
|
-9.84%
|
-2.38%
|
EPS
2 |
0.0848
|
0.003100
|
0.009200
|
-0.3944
|
-0.0959
|
-0.0305
|
Free Cash Flow
1 |
343.7
|
-79.71
|
398.3
|
207
|
-1,523
|
-54.37
|
FCF margin
|
55.26%
|
-12.69%
|
53.92%
|
28.96%
|
-191.39%
|
-5.2%
|
FCF Conversion (EBITDA)
|
297.26%
|
-
|
345.95%
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
495.04%
|
-
|
5,308.51%
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
19-04-22
|
20-04-23
|
21-04-26
|
22-04-27
|
23-04-25
|
24-04-25
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
226
|
579
|
569
|
513
|
674
|
703
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
1.956
x
|
5.263
x
|
4.946
x
|
-92.82
x
|
112.7
x
|
4.157
x
|
Free Cash Flow
1 |
344
|
-79.7
|
398
|
207
|
-1,523
|
-54.4
|
ROE (net income / shareholders' equity)
|
5.42%
|
0.18%
|
-0.61%
|
-42.7%
|
-8.47%
|
0.67%
|
ROA (Net income/ Total Assets)
|
1.12%
|
0.86%
|
0.51%
|
-1.89%
|
-1.63%
|
1.11%
|
Assets
1 |
6,219
|
294
|
1,468
|
17,045
|
4,801
|
-2,250
|
Book Value Per Share
2 |
1.430
|
1.260
|
1.590
|
1.190
|
1.710
|
1.670
|
Cash Flow per Share
2 |
0.1300
|
0.0400
|
0.0500
|
0.0500
|
0.1400
|
0.1300
|
Capex
1 |
53.3
|
109
|
202
|
367
|
161
|
198
|
Capex / Sales
|
8.57%
|
17.33%
|
27.39%
|
51.35%
|
20.29%
|
18.9%
|
Announcement Date
|
19-04-22
|
20-04-23
|
21-04-26
|
22-04-27
|
23-04-25
|
24-04-25
|
|
1st Jan change
|
Capi.
|
---|
| -13.78% | 607M | | -2.32% | 92.59B | | +3.68% | 41.43B | | -11.27% | 33.49B | | -19.38% | 14.62B | | -9.00% | 12.77B | | -11.34% | 11.58B | | -43.53% | 11.35B | | +3.75% | 8.97B | | -6.32% | 8.3B |
Biopharmaceuticals
|